Suggested remit: To appraise the clinical and cost effectiveness of oxybutynin hydrochloride (Vesoxx) within its marketing authorisation for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Technology proceeding to scope development.
Process TA
ID number 5089

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 August 2022 (10:00) Scoping workshop
07 July 2022 - 04 August 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 July 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual